Introduction {#tca12443-sec-0005}
============

Somatic mutations in the epidermal growth factor receptor (*EGFR*) are present in 30--50% of Asian patients with advanced non‐small‐cell lung cancer (NSCLC).[1](#tca12443-bib-0001){ref-type="ref"}, [2](#tca12443-bib-0002){ref-type="ref"}, [3](#tca12443-bib-0003){ref-type="ref"} *EGFR* sensitive mutations confer hypersensitivity to oral tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, in advanced NSCLC.[4](#tca12443-bib-0004){ref-type="ref"}, [5](#tca12443-bib-0005){ref-type="ref"}, [6](#tca12443-bib-0006){ref-type="ref"}, [7](#tca12443-bib-0007){ref-type="ref"}, [8](#tca12443-bib-0008){ref-type="ref"}, [9](#tca12443-bib-0009){ref-type="ref"} The detection of *EGFR* mutation (*EGFR*m) is therefore a critical step in prognosis and therapy selection for patients with advanced NSCLC. Although tumor tissue testing remains the recommended method for *EGFR*m detection,[10](#tca12443-bib-0010){ref-type="ref"} a multitude of barriers to biopsy exist, because *EGFR*m has invasive and heterogeneous characteristics and cannot reflect current tumor dynamics or sensitivity to treatment. Therefore, it is crucial to develop noninvasive methods for monitoring the real‐time dynamics of cancer.

A liquid biopsy of cancer‐related cell‐free DNA (cfDNA), termed circulating tumor DNA (ctDNA), may be an ideal solution. ctDNA is released into blood from apoptotic or necrotic tumor cells in primary, metastatic or circulating tumor cells, and contains identical genetic features with the corresponding tumor tissues.[11](#tca12443-bib-0011){ref-type="ref"}, [12](#tca12443-bib-0012){ref-type="ref"} Previous studies have proved the feasibility and reliability of analyzing *EGFR*m status in ctDNA.[13](#tca12443-bib-0013){ref-type="ref"}, [14](#tca12443-bib-0014){ref-type="ref"}, [15](#tca12443-bib-0015){ref-type="ref"}, [16](#tca12443-bib-0016){ref-type="ref"}, [17](#tca12443-bib-0017){ref-type="ref"}, [18](#tca12443-bib-0018){ref-type="ref"} Nonetheless, the investigation of ctDNA presents a substantial challenge, as approximately 30% of patients with *EGFR*m present discordant *EGFR*m status between tumor tissues and blood, especially patients with tumor tissues positive but blood negative for mutation. Even when highly sensitive methods, such as droplet digital PCR (ddPCR), which has a detection limit of 0.1--0.04%, are performed, a high rate of false negative (around 20%) has been observed.[11](#tca12443-bib-0011){ref-type="ref"}, [19](#tca12443-bib-0019){ref-type="ref"}, [20](#tca12443-bib-0020){ref-type="ref"} We therefore hypothesized that not only method sensitivity, but also the release, distribution, and clearance of ctDNA in blood contributes to false negative *EGFR*m in ctDNA.

Currently, the mechanism of ctDNA release into peripheral blood remains unclear, and the varying distributions and clearance of ctDNA in circulation at various time‐points have not been thoroughly investigated. Thus, in the present study, we prospectively and dynamically collected plasma from NSCLC patients to investigate the potential influence of the different sampling time within one day on *EGFR*m status. We also evaluated the correlation between *EGFR*m abundance and clinical outcomes in advanced NSCLC treated with EGFR‐TKIs.

Methods {#tca12443-sec-0006}
=======

Patient population {#tca12443-sec-0007}
------------------

To be eligible for the study, patients were required to have histologically confirmed, stage IIIB or IV NSCLC (classified as per the Union for International Cancer Control 7th edition Tumor Node Metastasis system), with *EGFR*m both in tumor tissues and plasma, no prior administration of systemic therapy, and available plasma samples. Patients treated at the Peking University Cancer Hospital or the Cancer Hospital Chinese Academy of Medical Sciences from July 2015 to April 2016 were recruited. The institutional review board at each hospital reviewed and approved the study. All patients gave informed consent for the collection of specimens and clinical information, and for biomarker analysis.

Sample collection and processing {#tca12443-sec-0008}
--------------------------------

Blood samples were collected in ethylene‐diamine‐tetraacetic acid vacutainer tubes at three different time‐points within one day (at 8 am, 11 am, and 2 pm) before first‐line *EGFR*‐TKI treatment, stored at 4°C, and processed within two hours. Blood samples were centrifuged at 1600 g at 4°C for 10 minutes for plasma collection, followed by a second centrifugation at 16 000 g for 15 minutes for further plasma clearance. Plasma was stored at −80°C until extraction. cfDNA was extracted from 2 mL of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), following the manufacturer\'s instructions. cfDNA was eluted in AVE buffer (Qiagen, Hilden, Germany). DNA samples were stored at −80°C until analysis.

Droplet digital (dd) PCR analysis for epidermal growth factor receptor mutation (EGFRm) {#tca12443-sec-0009}
---------------------------------------------------------------------------------------

The ctDNA was qualitatively and quantitatively analyzed by droplet digital (dd)PCR. The PCR reaction mixture (20 μL) contained 1× ddPCR Supermix (Bio‐Rad, Hercules, CA, USA), 0.9 pmol/μL of each primer and 0.45 pmol/μL of each probe (Amoy Diagnostics, Xiamen, China), and 50 ng of DNA template. The QX200 droplet generator was used to generate a maximum of 20 000 droplets for each sample (Bio‐Rad). Amplifications were performed under the following conditions: one cycle of 95°C for 10 minutes, followed by 45 cycles of 95°C for 15 seconds, 60°C for one minute, and then 4°C hold. Data acquisition and analysis was performed using QuantaSoft version 1.6.6 (Bio‐Rad). Four wells of negative controls with human reference genomic DNA (Promega Corporation, Madison, WI, USA), six wells of positive controls with 1:2500, 1:1000, and 1:2 ratios of mutant allele to wild type allele (genomic DNA from NCI‐H1650 cells for exon 19 deletion mutations and NCI‐H1975 cells for L858R mutations), and two wells of non‐template control were included in each run.[19](#tca12443-bib-0019){ref-type="ref"}

Statistical analysis {#tca12443-sec-0010}
--------------------

The variation of *EGFR*m abundance over time was analyzed with repeated measures analysis of variance (ANOVA) applying the Greenhouse‐Geisser epsilon correction to adjust for violations against the assumption of sphericity. An χ^2^ test was performed to assess the relationships between *EGFR*m status and each of the clinical and pathologic parameters; however, a Fisher\'s exact test was used for small sample sizes. Statistical analysis was performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA). A *P* value of \<0.05 was considered statistically significant.

Results {#tca12443-sec-0011}
=======

Patient characteristics {#tca12443-sec-0012}
-----------------------

Twenty‐two patients met the enrollment criteria and were recruited from July 2015 to April 2016. The final follow‐up date was 9 March 2017. All patients were initially diagnosed with stage IV lung adenocarcinoma, including eight men and 14 women. Sixteen patients were never‐smokers and six were former/current smokers. All cases were enrolled in trial NCT02282267 and had been identified as harboring *EGFR*m both in TKI‐naïve tumor tissue and plasma on different days, including 13 patients carrying exon 19 deletion mutations (E19‐dels), eight patients with L858R mutations, and one patient harboring L858R and T790M double mutations. None of the patients had received prior systemic therapy. Clinical and disease characteristics are listed in Table [1](#tca12443-tbl-0001){ref-type="table-wrap"}.

###### 

Patient clinical and disease characteristics

  Variables                                             No. of patients (*n* = 22)  \% of patients
  ---------------------------------------------------- ---------------------------- ----------------
  Age (years)                                                                       
  ≤60                                                               7               31.8
  \>60                                                              15              68.2
  Gender                                                                            
  Male                                                              8               36.4
  Female                                                            14              63.6
  Smoking history                                                                   
  Never smoker                                                      16              72.7
  Smoker                                                            6               27.3
  *EGFR*m                                                                           
  E19‐deletion                                                      13              59.1
  L858R                                                             8               36.4
  L858R/T790M[†](#tca12443-note-0001){ref-type="fn"}                1               4.5
  Metastatic organs                                                                 
  One                                                               11              50.0
  More than one                                                     11              50.0

One plasma DNA sample exhibited mutations at both L858R and T790M. EGFRm, epidermal growth factor receptor mutation.

Quantitative analysis of EGFRm in plasma by ddPCR {#tca12443-sec-0013}
-------------------------------------------------

To evaluate the effect of different sampling times on *EGFR*m test results, we prospectively and dynamically collected plasma from the 22 patients for *EGFR*m analysis by ddPCR. The frequency of *EGFR*m is summarized in Figure [1](#tca12443-fig-0001){ref-type="fig"}. The sample with L858R and T790M double mutations was included twice. Of the total 66 blood specimens, the median *EGFR*m frequency was 7.13% (range 0--35.09%), and among these six specimens had less than 1.0% *EGFR*m frequency. Of note, the *EGFR*m status in one patient switched from L858R mutation to wild type at different time‐points in the day (the fraction of *EGFR*m was 1.27, 2.74% and wild‐type, respectively, shown in Fig [2](#tca12443-fig-0002){ref-type="fig"}). The results demonstrated that the frequency of *EGFR*m in the ctDNA of each patient could change dynamically across different time‐points within one day. Repeated measures ANOVA was performed to analyze the variation in *EGFR*m frequency over time; however, no significant alterations were observed (*P* = 0.557). To identify whether correlations between the mutation status and the variation of *EGFR*m frequency existed, the patients were divided into two groups: E19‐dels (*n* = 13) and L858R mutation (*n* = 8). Because only one patient carried L858R and T790M double mutations, the T790M variation was excluded. However, repeated measures ANOVA revealed no significant correlation between them (*P* = 0.389).

![The dynamic variations of epidermal growth factor receptor mutation (EGFRm) frequency in plasma prospectively collected at three time‐points within one day (at 8 am, 11 am and 2 pm, respectively) from 22 patients (No. 5‐1 and no. 5‐2 are from the same plasma DNA sample, which exhibited mutations at both L858R and T790M. The EGFRm status of no. 16 at 2 pm was wild‐type).](TCA-8-312-g003){#tca12443-fig-0001}

![Detection of epidermal growth factor receptor mutation (EGFRm) status in no. 16 patient by droplet digital PCR. (**a**) Blood sample collected at 8 am harbored an L858R mutation (EGFRm frequency was 1.27%). (**b**) Blood sample collected at 11 am harbored an L858R mutation (EGFRm frequency was 2.74%). (**c**) Blood sample collected at 2 pm presented wild type.](TCA-8-312-g001){#tca12443-fig-0002}

Correlation between EGFRm frequency and gefitinib response {#tca12443-sec-0014}
----------------------------------------------------------

All of the patients received gefitinib as first‐line therapy. Using Response Evaluation Criteria in Solid Tumors, 13 (59.1%) patients achieved a partial response (PR), eight (36.4%) achieved stable disease (SD), and the patient (4.5%) with L858R and T790M double mutations was classified with progressive disease (PD). The objective response and disease control rates of patients were 59.1% (13/22) and 95.5% (21/22), respectively. The *EGFR*m detection results and clinical gefitinib outcomes are listed in Table [2](#tca12443-tbl-0002){ref-type="table-wrap"}.

###### 

EGFRm detection results and clinical outcome of gefitinib (n = 22)

  Case   *EGFR* mutation   Abundance of *EGFR* mutations   Response      PFS (months)        
  ------ ----------------- ------------------------------- ------------- -------------- ---- -----------------------------------------
  1      E19‐Dels          8.87                            7.77          10.64          PR   13.00
  2      L858R             6.70                            13.12         7.13           PR   5.17
  3      L858R             5.45                            5.83          9.02           SD   3.73
  4      E19‐Dels          17.09                           14.40         15.10          PR   [†](#tca12443-note-0001){ref-type="fn"}
  5      L858R/T790M       10.52/7.75                      14.01/12.15   12.19/12.30    PD   1.80
  6      E19‐dels          2.79                            3.89          3.03           SD   7.50
  7      L858R             8.97                            9.73          11.77          PR   [†](#tca12443-note-0001){ref-type="fn"}
  8      E19‐dels          19.05                           19.19         23.05          PR   [†](#tca12443-note-0001){ref-type="fn"}
  9      E19‐dels          7.33                            3.74          2.73           SD   [†](#tca12443-note-0001){ref-type="fn"}
  10     E19‐dels          1.39                            2.16          1.35           SD   5.53
  11     E19‐dels          0.33                            0.23          0.08           PR   8.40
  12     L858R             32.19                           29.36         29.24          PR   7.40
  13     L858R             0.46                            0.16          0.41           SD   10.27
  14     E19‐dels          32.34                           32.78         35.09          PR   11.17
  15     L858R             8.99                            6.77          5.69           PR   [†](#tca12443-note-0001){ref-type="fn"}
  16     L858R             1.27                            2.74          WT             SD   13.40
  17     L858R             5.44                            3.23          5.70           PR   [†](#tca12443-note-0001){ref-type="fn"}
  18     E19‐dels          4.11                            3.35          6.75           PR   11.97
  19     E19‐dels          4.70                            1.63          1.22           PR   [†](#tca12443-note-0001){ref-type="fn"}
  20     E19‐dels          6.06                            6.58          6.43           SD   9.30
  21     E19‐dels          28.43                           23.97         26.11          PR   4.10
  22     E19‐dels          9.08                            10.05         14.61          SD   [†](#tca12443-note-0001){ref-type="fn"}

No progress.

E19‐dels, E19‐deletions; EGFRm, epidermal growth factor receptor mutation; PD, progressive disease; PFS, progression‐free survival; PR, partial remission; SD, stable disease; WT, wild type.

To investigate the correlation between tumor response and variation in *EGFR*m frequency over time, we excluded the patient carrying L858R and T790M double mutations and divided the patients into four further groups, that is, patients who achieved: PR with E19‐dels (*n* = 8), PR with L858R mutation (*n* = 5), SD with E19‐dels (n = 5) and SD with L858R mutation (*n* = 3). However, repeated measures ANOVA revealed no significant differences (*P* = 0.740).

In order to evaluate the *EGFR*m fluctuation level to predict treatment response to gefitinib, we calculated the relative extent of *EGFR*m frequency fluctuation in each patient. We subtracted the minimum *EGFR*m frequency from the maximum in each patient, and divided the average *EGFR*m frequency at the three time‐points. A receiver operating characteristic (ROC) curve was then performed (Fig [3](#tca12443-fig-0003){ref-type="fig"}). ROC analysis showed that the area under the curve was 0.644 (95% confidence interval 0.388--0.900). From the ROC curves, the cut‐off reference value for the extent of fluctuation in *EGFR*m frequency was 0.493 (sensitivity 0.875, specificity 0.538). However, the difference did not reach statistical significance (*P* = 0.277).

![Receiver operating characteristic curve analysis results for extent of fluctuation in epidermal growth factor receptor mutation frequency to predict a treatment response to gefitinib.](TCA-8-312-g002){#tca12443-fig-0003}

We then calculated the average *EGFR*m frequency in these patients, who were then subdivided into two groups based on the relative extent of *EGFR*m frequency (median, 6.76%) in TKI‐ naïve plasma samples (group high: \>6.76%, *n* = 10; group low: ≤6.76%, *n* = 11). The patients with high *EGFR*m frequency at baseline had a better response to gefitinib compared to those with low *EGFR*m frequency (*P* = 0.024). Selected characteristics of patients with different *EGFR*m frequency are shown in Table [3](#tca12443-tbl-0003){ref-type="table-wrap"}.

###### 

Selected characteristics of patients with different EGFRm frequency (n = 21[†](#tca12443-note-0004){ref-type="fn"})

  Variables           Low abundance (*n* = 11)   High abundance (*n* = 10)   *P*          
  ------------------- -------------------------- --------------------------- ----- ------ -----
  Age (years)         0.361                                                               
  ≤60                 9                          81.8                        6     60.0   ---
  \>60                2                          18.2                        4     40.0   ---
  Gender              0.387                                                               
  Male                3                          27.3                        5     50.0   ---
  Female              8                          72.7                        5     50.0   ---
  Smoking history     0.361                                                               
  Never smoker        9                          81.8                        6     60.0   ---
  Smoker              2                          18.2                        4     40.0   ---
  Metastatic organs   0.395                                                               
  One                 7                          63.6                        4     40.0   ---
  More than one       4                          36.4                        6     60.0   ---
  Tumor response      0.024                                                               
  PR                  4                          36.4                        9     90.0   ---
  SD                  7                          63.6                        1     10.0   ---

Excludes the patient carrying L858R and T790M double mutations.

Factors were tested by χ^2^ or Fisher\'s exact tests.

EGFRm, epidermal growth factor receptor mutation; PR, partial remission; SD, stable disease.

Discussion {#tca12443-sec-0015}
==========

To our knowledge, the present study represents the first prospective investigation of the potential influence of different time‐points of blood collection on *EGFR*m status. Moreover, we also evaluated clinical outcomes according to the quantity of *EGFR*m in advanced NSCLC. The results demonstrated that the frequency of *EGFR*m in plasma could change dynamically across different time‐points within one day, but no significant alterations were observed in changes to *EGFR*m frequency over time. Moreover, patients with high *EGFR*m frequency (\>6.76%) at baseline had a better response to gefitinib compared to those with low *EGFR*m frequency (≤6.76%).

Liquid biopsy of cancer‐related cfDNA has been a research hotspot because of its homogeneity and noninvasive, dynamic monitoring characteristics. However, multiple preanalytic factors, such as sample collection, sample processing, storage conditions, and DNA isolation methods, could compromise the accuracy cfDNA measurements.[21](#tca12443-bib-0021){ref-type="ref"}, [22](#tca12443-bib-0022){ref-type="ref"}, [23](#tca12443-bib-0023){ref-type="ref"}, [24](#tca12443-bib-0024){ref-type="ref"} Furthermore, the investigation of ctDNA has presented substantial challenges, as ctDNA often represents at extremely low fractions (\<1.0%) of total circulating cfDNA.[11](#tca12443-bib-0011){ref-type="ref"} Technological advances have overcome this restriction, making it possible to enumerate the rare mutant variants in a complex mixture of DNA. However, in our previous study, although we exhaustively eliminated the influence of preanalytic factors and a high sensitivity method was adopted, a considerable proportion of false negative results still emerged.[20](#tca12443-bib-0020){ref-type="ref"} This result suggests that other variables influencing *EGFR*m testing may exist.

Presently, the mechanism of ctDNA release and its distribution and clearance are not well understood as the amount of ctDNA released into the circulation may be different at different clinical stages, treatment periods, or even different time‐points within one day. A previous study suggested that ctDNA has a relatively short half‐life (approximately two hours).[25](#tca12443-bib-0025){ref-type="ref"} In this regard, the release of ctDNA is a continuous process. In this study, blood samples were conveniently collected at three hour time points (at 8 am, 11 am and 2 pm). Preanalytic factors that could influence measurement and analysis were exhaustively eliminated. The results indicated that *EGFR*m frequency was not stable over the course of a day (and even switched from positive to negative in one patient), which may suggest that temporal heterogeneity of ctDNA shedding. In healthy individuals, infiltrating phagocytes clear apoptotic and necrotic cells. Nevertheless, infiltrating phagocytes do not function efficiently in certain situations, such as in advanced‐stage cancers, leading to the accumulation of cellular remains, which are then released into the circulation. As \<10 of circulating tumor cells exist per 7.5 mL blood,[26](#tca12443-bib-0026){ref-type="ref"} passive release from apoptotic and necrotic cells is likely the primary source of ctDNA in circulation.[12](#tca12443-bib-0012){ref-type="ref"} The passive release of ctDNA is dependent on tumor location, volume, and/or vascularity.[11](#tca12443-bib-0011){ref-type="ref"} In this study, both drastic variation in *EGFR*m frequency and *EFGR*m status (which switched from positive to negative in one patient), suggest the possibility that the ctDNA release process is not homogeneous. At certain time‐points, infiltrating phagocytes clear most or all cellular debris and highly sensitive techniques, such as ddPCR, cannot detect ctDNA mutation. However, no significant differences were observed in the changes in *EGFR*m frequency over time in our study. There are several possible reasons for this phenomenon. First, as a consequence of temporal heterogenenous release, variation in *EGFR*m frequency is chaotic. Second, the rhythm of *EGFR*m frequency variation has not been ascertained because of the small sample size of the study and/or the sampling time‐points were unreasonably arranged.

Our study also indicated that a relatively high frequency of *EGFR*m in plasma could predict a better clinical response to gefitinib. To our knowledge, Zhou *et al.* were the first to reveal that relative *EGFR*m frequency in tumor tissues could predict the extent of benefit from EGFR‐TKI treatment for advanced NSCLC.[27](#tca12443-bib-0027){ref-type="ref"} However, spatial and temporal heterogeneity represents a major obstacle to therapeutic guidance reliant on biopsy throughout the entire process of treatment, especially after disease progression. Yung *et al.* quantified *EGFR*m in plasma by digital PCR and proved the relationship between *EGFR*m concentration and clinical response.[28](#tca12443-bib-0028){ref-type="ref"} Yang *et al.* indicated that advanced NSCLC patients with high *EGFR*m abundance in TKI‐ naïve plasma showed better progression‐free survival compared to those with low *EGFR*m frequency.[20](#tca12443-bib-0020){ref-type="ref"} In this study, all of the patients carried *EGFR*m, both in TKI‐naïve tumor tissue and plasma, which avoided false positive results in ctDNA. Our results indicate that patients with a high frequency of *EGFR*m (\>6.76%) in ctDNA at baseline had a better response to gefitinib. Theoretically, the frequency of intratumor *EGFR*m is associated with tumor burden[11](#tca12443-bib-0011){ref-type="ref"}, [29](#tca12443-bib-0029){ref-type="ref"} and the proportion of TKI‐sensitive mutant clones in whole tumor clones. Therefore, patients with a relatively high frequency of *EGFR*m obtained a better response to TKIs and had longer progression‐free survival. Nevertheless, the level of fluctuation in *EGFR*m did not reflect *EGFR*m frequency, therefore the level of fluctuation could not predict a tumor response to gefitinib.

The limitations of this study include the small sample size and no nighttime sampling was conducted. Future studies are needed to evaluate the reliability of dynamic changes in ctDNA within one day. Moreover, additional studies are required to evaluate the predictive value of baseline ctDNA in patients treated with EGFR‐TKIs.

In summary, our results suggest that ctDNA release maybe a temporal heterogenous process and different sampling time‐points do not seem to influence *EGFR*m status in ctDNA. The relative *EGFR*m frequency in ctDNA could predict a benefit from EGFR‐TKI treatment for advanced NSCLC patients. A prospective study with a specific design is warranted in the future.
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